stockportfolio.pro
Collegium Pharmaceutical, Inc. P/E Ratio 2013–2025
Collegium Pharmaceutical, Inc. (COLL) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +0.1%/yr over 12 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 26.76 | +73.7% |
| FY 2024 | 15.40 | -35.4% |
| FY 2023 | 23.86 | — |
| FY 2022 | — | — |
| FY 2021 | 10.04 | -61.9% |
| FY 2020 | 26.36 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
Source: Collegium Pharmaceutical, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Collegium Pharmaceutical, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCollegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s price-to-earnings ratio?
Collegium Pharmaceutical, Inc. (COLL) reported price-to-earnings ratio of 26.76 for fiscal year 2025, per its SEC filings.
How has Collegium Pharmaceutical, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2013 and 2025, COLL's price-to-earnings ratio grew at roughly 0.1% per year (compound annual rate), from 26.36 to 26.76.
Where does this data come from?
Figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.